CinnaGen
Siavash Eftekhari is a seasoned financial and economic advisor currently serving the Board of Directors at CinnaGen Pharmaceutical Company since August 2022, providing strategic financial guidance in collaboration with the COB-CEO and executive team. Prior to this role, Siavash held various positions at Exir Pharmaceuticals Company from December 2012 to August 2022, including Finance Manager, Budgeting & Reporting, and Head of Financial Accounting, where responsibilities encompassed oversight of the company's financial affairs. Siavash's educational background includes a Doctor of Philosophy in Accounting and Finance, a Master of Science in Accounting and Finance, and a Bachelor of Science in Accounting and Finance, all obtained from Islamic Azad University, as well as a Diploma of Education in Empirical Science from Shahed School.
This person is not in any teams
This person is not in any offices
CinnaGen
CinnaGen Co. has founded in 1994 with the goal of manufacturing High-Tech products in biotechnology and related fields. Since its start of operations with 4 scientists, CinnaGen has grown to become the biggest Biopharma manufacturer and biotech exporter in the region. The concept was to be active in the research and development of new potent biotech-based products for covering regional market. Enzymes, molecular biology reagents and PCR kits are the first products and then CinnaGen use its proprietary set of technologies to endow Monoclonal Antibodies for blood group typing. The next important step for CinnaGen was the entry to the therapeutic recombinant protein area. Today the company prides itself in its innovative skills meeting today’s challenges. We focus our efforts on developing the biogenerics candidates in the areas of immunological diseases and oncology as well as providing contract research development services. The company is spending over 20 percent of its total turnover on R&D activities. CinnaGen is strategically positioned to become and remain leading biotechnology company in the region. Our aim is to use our expertise to identify and acquire selected products, through strategic partnerships to promote sustainable development in human health.